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  68 
Abstract 69 
Autism Spectrum Disorder (ASD) is a construct used to describe individuals with a specific combination 70 
of impairments in social communication and repetitive behaviours, highly restricted interests and/or 71 
sensory behaviours beginning early in life. The worldwide prevalence of ASD is just under 1%, but 72 
estimates are higher in high-resource countries. Although gross brain pathology is not characteristic of 73 
ASD, subtle anatomical and functional differences have been observed in postmortem, neuroimaging 74 
and electrophysiological studies. Initially it was hoped that accurate measurement of behavioural 75 
phenotypes would lead to specific genetic subtypes, but genetic findings have mainly applied to 76 
heterogeneous groups that are not specific to ASD. Psychosocial interventions in children can improve 77 
specific behaviours, such as joint attention, language and social engagement that may affect further 78 
development and could reduce symptom severity. However, further research is necessary to identify the 79 
long-term needs and treatments and the mechanisms behind them that could result in improved 80 





with ASD throughout much of life and need to be considered, along with the perspectives of autistic 82 
persons, in both research and practice. 83 
 84 
 85 
[H1] Introduction  86 
Autism spectrum disorder (ASD) is a common, highly heritable and heterogeneous neurodevelopmental 87 
disorder that has underlying cognitive features and commonly co-occurs with other conditions. The 88 
behaviours, strengths and challenges of people with autism, or ASD, have attracted the attention of 89 
scientists and clinicians for at least 500 years (Fig. 1). ASD is a heterogeneous disorder and, reflecting this 90 
heterogeneity, the term autism has been used in various ways to describe both a broader presentation, 91 
and then a specific diagnosis when it was considered to be one subgroup within the general diagnostic 92 
category of ‘pervasive developmental disorders’ (PDDs), a group of disorders that was introduced in 93 
Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III) in 1980 to convey the idea 94 
of a broader spectrum of social communication deficits. Owing to of lack of clear borders between the 95 
PDDs and difficulties in reliably distinguishing them, the current diagnostic systems, the International 96 
Classification of Diseases 11th Revision (ICD-11) and the DSM-5 use the umbrella term ‘ASD’, and 97 
differentiate individuals using additional clinical specifiers and modifiers.  98 
Manifestations of ASD include impairments in social communication and interaction, sensory anomalies, 99 
repetitive behaviours and varying levels of intellectual disability (Table 1). Together with these core 100 
symptoms, co-occurring psychiatric or neurological disorders are common in people with ASD, of which, 101 
hyperactivity and attention disorders (such as attention-deficit/hyperactivity disorder (ADHD)), anxiety, 102 
depression and epilepsy are fairly prevalent. A diagnosis of ASD is reached after obtaining a detailed 103 
developmental history, often from the parents, and observation of the individual interacting with parents 104 
or other individuals 1,2. Early intervention for children with ASD is key owing to common difficulties in 105 
communication. The types of interventions used change throughout life and include parent-mediated 106 
interventions and/or therapist-delivered interventions in childhood, school-based strategies and 107 
techniques to promote independence in adulthood. Pharmacological therapies can be used to treat some 108 
of the associated symptoms of ASD, such as irritability, and comorbidities, such as anxiety.  109 
This Primer discusses the epidemiology and mechanisms of ASD, together with the diagnosis and 110 
treatment of people with this condition. Three themes are addressed: mechanisms of causality and 111 
change over time, heterogeneity within and between individuals with ASD, and outcomes across the 112 
lifespan. 113 
 114 
[H1] Epidemiology 115 
[H2] Prevalence [Au: subheading introduced for flow, OK?YES]  116 
Epidemiological administrative and community-based [Au:OK?YES] studies have suggested that ASD is 117 
more common in males than in females, with reported ratios [Au:OK to add ‘with reported ratios’ here?] 118 
ranging from 2.1–5. 1, with an estimate of 4.1 in the 2010 [Au:OK?] Global Burden of Disease study3,4. The 119 
sex ratio is slightly lower in studies that use population-wide testing  [Au: I’ve edited ‘screening’ to 120 
‘population-wide testing’ here based on this comment. Do we need to edit the text in the Diagnosis, 121 





more common passive case-finding studies that review administrative data (for example, medical or 123 
special educational records), and that may result in less plausible associations and, therefore, artificially 124 
increase prevalence estimates 5. Active case-finding that does not rely on administrative records has 125 
demonstrated an equivalent community rate of ASD in men and women with moderate to profound 126 
intellectual disability4. Thus, even the most widely accepted tenet of our understanding of factors 127 
associated with ASD is far from straightforward.  128 
Estimates of the prevalence of ASD in various populations and settings differ according to the method of 129 
ascertainment used in the study, including definition, sampling and the extent of independent population 130 
case assessment. Of note, the Global Burden of Disease study uses all known data from administrative 131 
and community survey sources on a disease or disorder to model associations (particularly with time) to 132 
examine trends. In the 2010 GBD study [Au:OK?] , an estimated 52 million people had ASD globally, 133 
equating to a prevalence of 1 in 132 individuals6. Worldwide, little interpretable variation in the 134 
prevalence of ASD between regions or ethnicities has been reported [Peer reviewer comment: It would 135 
be useful to add a few comments about prevalence estimates around the world and how they differ 136 
based upon resources of the countries (i.e., are likely not due to regional variations in prevalence or 137 
differing environmental conditions, but instead reflect access to services). This could enhance the 138 
paper’s global perspective. [Au: could we quote additional data from the GBD study here? If these data 139 
are lacking I would mention this here so it’s clear to readers]. Indeed, one systematic review did not find 140 
a strong effect of ethnic, cultural or socioeconomic factors on the prevalence of autism [Au:OK] 7. 141 
However, statistical power to detect any effects was limited in the available data sets, particularly in low-142 
income countries. An increased prevalence of ASD has been reported in migrant groups in some studies 8 143 
with few clear factors that might contribute to a greater prevalence in an Afro-Caribbean population in 144 
higher income countries 9,10,11 in the absence of any evidence of geographical variation 7. However, a 145 
survey of adults in the general population has shown that rates of ASD in black and minority ethnic groups 146 
may be lower than in the rest of the population 12; data from indigenous and Aboriginal cultures are very 147 
limited.  148 
Many individuals and groups presume that autism rates are increasing over time, but this supposition is 149 
based on data from administrative records rather community-based studies. Indeed, after accounting for 150 
methodological variations between studies, there was no clear evidence of a change in the prevalence of 151 
ASD in the community between 1990 and 201013. In addition, general population and systematic case-152 
finding community-based [Au:OK?] surveys (including testing of representative populations) have also 153 
confirm the lack of significant change in prevalence rates in childhood14 and adulthood15 over time. No 154 
significant evidence is available supporting that ASD is rarer in older people, which provides further 155 
evidence against the suggestion that ASD is increasing in prevalence over time4. Even in high-income 156 
countries with strong ASD public health policies, there is evidence that ASD in adults goes largely 157 
unrecognized, whereas administratively recorded diagnoses in children increase year by year16. This 158 
finding highlights the importance of obtaining information on ASD rates in settings where professionals 159 
may be able to improve its recognition. The prevalence of ASD in mental health inpatient settings is 160 
estimated to be far higher than in the general population, ranging from 4–9.9%17.  161 
 162 





One review of systematic reviews and meta-analyses of environmental risk factors for ASD included a 164 
comprehensive coverage of the literature, a discussion of the limitations of research and the need for 165 
long-term prospective cohort-based studies to begin to address these limitations 18 (Fig. 2). This and other 166 
studies identified environmental risk factors for ASD as advanced parental age19 and birth trauma, 167 
particularly if due to proxies of hypoxia18. Moreover, maternal obesity, a short interval between 168 
pregnancies, gestational diabetes mellitus and valproate use during pregnancy have all been associated 169 
with increased risk of ASD [Au:OK?] (Fig. 2). However, it should be noted that these factors cannot be 170 
considered causal, but could be reactive, independent or contributory for ASD. Studies evaluating risk 171 
factors for ASD that have reported an absence of association are equally, if not more important, to note, 172 
including clear evidence that ASD is not associated with vaccination20. Other negative associations include 173 
prolonged labour, delivery by caesarian section or assisted vaginal delivery, premature rupture of 174 
membranes and the use of assisted reproductive technologies, among other factors (Fig. 2). 175 
Environmental risk factors could underlie risk of ASD through several complex underlying mechanisms, 176 
such as [Au: edits to improve narrative flow ok?] genetic and epigenetic related effects (see 177 
Mechanisms/pathophysiology, below), inflammation and oxidative stress, hypoxic and ischemic 178 
damage18.  179 
 180 
[H1] Mechanisms/pathophysiology  181 
Many cognitive theories have been suggested to underlie the behavioural and developmental 182 
manifestations of ASD, although the prominence and the consensus on the potential explanatory value of 183 
these theories have declined in the past decade. These theories range from ‘social first’ theories, such as 184 
the theory of mind (or mentalizing) and social motivational deficit theories, to global processing deficit 185 
theories including attentional control, executive dysfunction and weak central coherence or enhanced 186 
perceptual processing theories 21,22. Although many of these theories had a useful descriptive role and 187 
provide potential insights into differences in how autistic individuals might process and experience the 188 
world around them, the theories pertain to neurodevelopmental disorders in general and lack specificity 189 
for ASD), largely non-developmental, applying only to a single point in time, and lack evidence as 190 
explanatory models. Nevertheless, they have been useful in clinical practice and underlie some recently 191 
proposed interventions, such as CBT-oriented treatments for anxiety23.  192 
Following cohorts of infants from gestation or birth to 2 or 3 years of age (that is, when a diagnosis of ASD 193 
can be established) enables the study of the brain and behavioural manifestations of ASD as they 194 
emerge24. Indeed, prospective studies of infants with a relative with ASD have yielded a number of insights 195 
into the mechanisms of this disorder. For example, infants who develop ASD later in childhood have 196 
substantially typical profiles of interest in faces25 and eyes26 at 6 months of age, which have cast doubt on 197 
social orienting theories in which ASD originates from a primary deficit in innate patterns of subcortically-198 
mediated social orienting27. In addition, subtle but diffuse differences in encephalography (EEG) and in 199 
other measures of brain function have been demonstrated in autistic people (see ‘Findings from 200 
electrophysiological studies’, below), which could represent alternative pathways to a common end-state 201 
phenotype or to whole-brain alterations in  synaptic signalling pathways that have effects on development 202 
[Au: edits for brevity ok?] 28. Such considerations highlight the limitations of deterministic models of ASD, 203 





is likely a complex set of developmental interactions, in which the child’s emerging brain activity and 205 
behaviour have bidirectional relationships to synaptic signalling and gene expression30. 206 
 207 
[H2] Genetics  208 
Twin and family studies consistently demonstrate that ASD has a particularly large genetic contribution, 209 
with estimated heritability ranging from ~40 to 90%31,32. In addition, one analyses demonstrated that ASD 210 
is among the most heritable common medical conditions33. More than 100 genes and genomic regions 211 
have now been confidently associated with ASD34,35, mostly based on the study of heterozygous, germ-212 
line, de novo mutations. These genetic changes range in size from a single base (or nucleotide)36–38 to 213 
submicroscopic segments of DNA of thousands to millions of bases (also known as copy number variations 214 
(CNVs))39,40. Whether these genetic changes lead to alterations in the sequence of DNA or the structure 215 
of the chromosome, changes that have a functional effect on protein-coding regions of the genome have 216 
the strongest and most reliable association with ASD risk. Collectively, these de novo heterozygous 217 
mutations are rare and confer relatively large risks of ASD 41. With genetic studies now including cohorts 218 
of up to tens of thousands of individuals and the associated increase in statistical power, common, 219 
transmitted alleles of modest effect size, mostly corresponding to the non-coding regions of the genome, 220 
have begun to be identified42.  221 
Studies of the genetics of ASD contrast broadly with studies of adult-onset psychiatric disorders, in which 222 
most successful gene discovery has emerged from genome-wide association studies (GWAS), which assess 223 
common alleles of small effect size. Indeed, the earliest successes in ASD presaged a more general finding 224 
that the contribution of rare, de novo mutations in coding regions of the genome is relatively greater 225 
among a range of early-onset disorders43–45 than for typically later-onset common conditions such as 226 
schizophrenia and bipolar disorder, although there is also a surprising degree of overlap in genetic risk for 227 
overtly disparate neuropsychiatric phenotypes that remains to be further elucidated31.  228 
The extent to which rare, high effect size mutations account for ASD risk raises some important 229 
definitional issues. Considering the overall population, the contribution of de novo mutations to ASD risk 230 
is quite small (~3%)32. Indeed, the vast majority of individuals who harbour genetic risk for a common 231 
condition, particularly those with variants of small effect size, will never develop symptoms or need clinical 232 
attention. By contrast, there is a marked enrichment of individuals with rare and de novo mutations in 233 
the clinical ASD population. Conservative estimates are that 10–20% of people with ASD harbour a de 234 
novo rare point mutation or CNV contributing to their presentation (34,  49,50). If the clinical population 235 
is constrained to those with ASD who are female or who have intellectual disability, multiple unaffected 236 
siblings or seizures, ~20-30% have a rare de novo mutation [Au: edits for clarity based on Matt’s 237 
comment, ok?] 34. For example, the yield of de novo structural and sequence variations contributing to 238 
ASD is nearly double in girls than in boys (34).  239 
However, irrespective of the precise proportion of risk conveyed by these mutations, their most 240 
substantial contribution to the understanding of ASD is likely to be in elaborating the mechanisms of this 241 
disorder48,49. In ASD, a single de novo germ-line heterozygous loss-of-function point mutation can convey 242 
more risk than the cumulative effect of the top decile of polygenic risk for schizophrenia47,50. 243 





addressing a single ASD mutation at a time is not synonymous with an easy avenue to clinical care of most 245 
people with ASD.  246 
[H3] Molecular pathophysiology. Over the past decade there have been many studies using model 247 
systems to recapitulate so-called single gene (or monogenic) versions of ASD, such as fragile X syndrome 248 
and tuberous sclerosis complex – which cumulatively are estimated to account for <10% of clinical cases 249 
of ASD51. In addition, more recent studies have modelled the effects of rare and de novo mutations 250 
identified in idiopathic ASD. This literature is far too vast to review comprehensively here 52,53. Although 251 
the study of ASD risk genes in model systems has revealed a great deal about general biology, how these 252 
findings relate to the pathophysiology of ASD is less clear48,49. In general, ASD risk genes tend to have a 253 
role in multiple functions in many brain regions that unfold in a spatiotemporally defined manner across 254 
development. Consequently, although manipulation of a single risk gene in a model system may lead to 255 
interesting phenotypes—including social-behavioural phenotypes in evolutionarily distant organisms— it 256 
does not necessarily illuminate its contribution to human social disability. Moreover, although a single 257 
mutation can confer a several fold increase in the risk of ASD, these variants do not demonstrate the type 258 
of causal clarity that is associated with classic monogenic neurodevelopmental disorders, such as fragile 259 
X syndrome, Angelman syndrome, Rett syndrome or tuberous sclerosis complex. In addition, the well-260 
established sexual dimorphism of social disability adds yet another dimension to the expansive search 261 
space that exists between risk gene and human behaviour48. The challenges of disentangling the 262 
spatiotemporal dynamics of risk gene expression and protein function are made even more difficult by 263 
the reality that these may play out differently in males versus females. 264 
Owing to these challenges, multiple approaches have emerged focusing on convergence38,40,54–57, that is, 265 
searching for points of commonality across different ASD risk genes, with the reasoning that this approach 266 
could identify shared pathological mechanisms. In fact, the earliest successes in gene discovery quickly 267 
revealed important general properties that have held up well over time, including that, prima facie, most 268 
proteins encoded by ASD risk genes are involved either in synaptic structure and function or chromatin 269 
modification and regulation of gene expression38,46,47,58 (Fig. 3). More recently, there has been an 270 
additional focus on spatiotemporal convergence and several studies have supported a nexus in mid-fetal, 271 
glutamatergic neurons during cortical development, with modestly divergent findings regarding deep 56 272 
versus superficial54 cortical layers. With improvements in technology, additional regions, including 273 
striatum, have also begun to emerge as points of potential risk convergence for ASD59.  274 
The ability to constrain future experiments to examine mutations in specific risk-associated regional, 275 
cellular and developmental contexts should allow the narrowing in on relevant mechanisms. Of note, one 276 
study used single cell technologies to examine specific cell types and developmental stages using brain 277 
tissue from people with ASD 60, and demonstrated changes in transcription in multiple cell types including 278 
upper-layer cortical neurons. These types of post-mortem studies ask important but somewhat broader 279 
questions from the approaches described above, such as underlying pathology and how the brain changes 280 
and responds to pathology over time. In these studies, similar to any cross-sectional study, it can be 281 
challenging to differentiate cause from effect. Consequently, the pursuit and intersection of studies that 282 
seek to define convergence early in development and those that examine subsequent molecular, cellular 283 






[H2] Neurobiology 286 
[H3] Findings from MRI Studies. This section does not summarize the structural or functional 287 
literature and focuses predominantly on prospective study designs. Broader coverage of the 288 
neurobiology of ASD is needed] [Au: I suggest adding a sentence or two at the end of this paragraph 289 
summarizing Rebecca’s comment here, so it’s clear why this section of the paper focuses on prospective 290 
studies and those in infants] MRI can facilitate understanding how the brain structurally and functionally 291 
develops differently in people with ASD, although to date, MRI results in ASD are not definitive. Although 292 
neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, 293 
sometimes that is related to head motion that occurred during the scan which can erode signal61, 294 
structural studies including those using diffusion tensor imaging (DTI)62 and functional MRI (fMRI)63 have 295 
accelerated our understanding of how altered neural circuits relate to clinical symptoms of ASD64,65. 296 
Studying circuitry in childhood that is specifically associated with the social brain (a network of brain areas 297 
involved with processing social information), including visual areas, areas of the prefrontal cortex, 298 
subcortex and areas integrating information (such as temporal parietal function and superior temporal 299 
sulcus), could also offer insight into the neural mechanisms of ASD 66. In addition, MRI may facilitate 300 
understanding the heterogeneity of ASD demonstrating subgroups of individuals with specific 301 
neurobiological alterations that could account for their symptomology.  302 
The first MRI studies of ASD focused on cerebral and cerebellar grey matter and white matter volumes in 303 
young children67,68, although these studies were limited by studying toddlers and children ≥18 months, 304 
missing the opportunity to detect biomarkers of ASD in the first year of life. More recently, longitudinal 305 
studies have obtained multiple brain MRIs of infants at high risk of developing ASD (that is, those with a 306 
sibling with ASD; known as baby sibling studies) during their first 2 years of life, and assessed these 307 
children for ASD at this age. In these studies, detectable differences in brain structure were observed at 6 308 
months of age in the fractional anisotropy trajectories for 12 of 15 neural fibre tracts in the brain in 309 
children diagnosed with ASD at 2 years of age compared to children not diagnosed69. Furthermore, 310 
abnormal growth in the cortical surface between 6 and 12 months of age and greater brain volume 311 
between 12 and 24 months of age was seen in children who were later diagnosed with ASD, compared 312 
with those not diagnosed with ASD70 (Fig. 4). In addition, white matter integrity in the genu pathway at 6 313 
months of age predicted the presence of restricted and repetitive behaviours at 2 years of age71 and 314 
computational work demonstrated that whole brain functional connectivity at 6 months of age predicted 315 
a diagnosis of ASD at 2 years of age72. Collectively, these studies suggest the presence of disrupted neural 316 
pathways before the emergence of behavioural symptoms in children with ASD, and might provide clues 317 
about the underlying neural mechanisms of ASD. Although data from MRI studies has revealed differences 318 
in neurobiology between young children diagnosed with ASD and those without73, given that replication 319 
has been particularly difficult in these studies, more work is required before MRI can be used as a reliable 320 
biomarker of ASD74.  321 
Task-based fMRI studies investigate circuits that are responsible for core challenges in ASD (such as 322 
language production and comprehension75), and have demonstrated hyper-activation of the superior 323 
temporal gyrus and inferior frontal gyrus and hypoactivation of the bilateral middle temporal gyrus72. In 324 
addition, these studies have demonstrated challenges in processing emotions in faces and the “social 325 
brain”74, and deficits in attention75. Studies have also shown greater sensitivity to sensory information, 326 





insula and amygdala, together was associated with greater sensitivity to slightly aversive sounds and 328 
tactile information76. Although this area of research has revealed similarities or differences in people with 329 
ASD compared with comparison groups, it has been limited by averaging data across many individuals, 330 
which can mask heterogeneity and differences across age groups. In addition, the work has been limited 331 
by small sample sizes and problems with replication that is likely caused by the many challenges with MRI 332 
data collection in people with ASD, such as differences in data processing, inter-subject variability and 333 
data quality76. Longitudinal imaging77 as well as associating neuroimaging data with longitudinal 334 
behavioural outcomes78 can address some of these limitations characterizing differences within 335 
participants.  336 
Resting state functional connectivity MRI studies that require participants to look at a blank screen with 337 
no task demands have been used to study intrinsic connections in the human brain. Large datasets, such 338 
as the Autism Brain Imaging Date Exchange (ABIDE79), have enabled researchers to pool data to allow 339 
more highly powered studies to address known limitations of small sample sizes and many dataset have 340 
relied on resting state studies to study neural connectivity in ASD. In these studies, evidence has emerged 341 
of both hyper-connectivity and hypo-connectivity in short-range and long-range connections throughout 342 
the brain80,81. Differences in results between studies could be due to the age of the participants82, sex 343 
differences, heterogeneity, methodological concerns83 or that both connectivity states exist in ASD. 344 
In future, MRI could be well suited to categorize subgroups of ASD84, as well as parsing out commonalities 345 
and distinctions among other developmental disorders85. Using MRI to better understand differences 346 
between boys and girls on the spectrum86, such as differences in whole brain connectivity 86 or the social 347 
brain87, a field in its infancy, or as a marker of biological change due to treatment has growing interest 88.  348 
[H3] Findings from electrophysiological studies. EEG has been historically used for the 349 
diagnosis of comorbid epilepsy in people with ASD89 although it can also be used to study the mechanisms 350 
of ASD. Compared with MRI, EEG is more economical, easier to use and less invasive—which is particularly 351 
important for paediatric populations—whilst granting access to brain dynamics at millisecond timescales. 352 
Magnetoencephalography (MEG), although more expensive, provides higher spatial resolution than EEG.  353 
Since the early recordings, the first focus of quantitative EEG was to study people with ASD in task-free 354 
conditions. Pioneering studies have revealed alterations in oscillatory activity during the resting state in 355 
people with ASD, with more slow waves and less alpha waves, as well as less intra-hemispheric and inter-356 
hemispheric asymmetry compared to people without ASD 90. More recent work has demonstrated the 357 
presence of developmental trajectories as revealed through increasingly sophisticated spatio-spectral 358 
analyses, and has revealed how differences in the trajectories of EEG power in high-risk infants may 359 
represent an endophenotypes of ASD 91,92.  360 
In terms of mechanisms, other studies have started to focus on task-based modulation of cognitive 361 
function, such as low-level perceptual anomalies and action observation that relate to the ASD phenotype. 362 
One theory proposing a specific failure in ASD of the ability of the brain to ‘mirror’ observed actions of 363 
another person (thereby named the ‘broken mirror’ theory) was based on altered μ-wave suppression in 364 
ASD93 but was later questioned both theoretically94,95 and empirically96,97, pointing toward a more complex 365 
picture of dysfunctional executive functions and visual attention98. Other studies, particularly those 366 
assessing event-related potentials (ERP), have demonstrated the modulation of sensory processing in 367 





processing could have a role in the development of core features of ASD, such as language delay and 369 
difficulty in emotion recognition although this hypothesis requires further study. Although perceptual 370 
processes appear different in people with ASD, the electrophysiological underpinning is still far from clear 371 
regarding the main ERPs like the MisMatch Negativity (MMN)100 or the N170101. Although data from 372 
metanalyses have suggested smaller MMN amplitudes and delayed N170 latencies on average in people 373 
with ASD compared to typically developing controls, additional studies are required that account for the 374 
large heterogeneity of this disorder, by moving away from averaging the data to focus either on specific 375 
subgroups102 or refined modelling strategies that can capture individual differences in developmental 376 
trajectories91. Although this avenue of research has not yet been fully explored, interactive tasks that 377 
encompass real-time social interaction could allow the study of brain activity in experimental contexts 378 
that are more relevant for core ASD symptoms, rather than the more passive tasks that are used in most 379 
functional imaging studies 103. Experiments focusing on human-human interaction104 and human-machine 380 
interaction105 have been undertaken but, so far, no study has ever made explicit use of such methods to 381 
study the electrophysiology of ASD. 382 
In a further search for mechanisms of ASD, prospective baby siblings studies have suggested that the 383 
gradual emergence of behavioural symptoms of ASD is preceded by earlier subtle alterations in the activity 384 
of regions and networks of the social brain24. For example, early work on a small group of 5–6-month-old 385 
infants who later developed ASD observed faster but less prolonged neural activation and delayed 386 
sensitization responses to faces compared with infants who did not develop ASD 106, and one report 387 
demonstrated that newborns with an increased familial likelihood of ASD showed higher signal 388 
homogeneity within core social brain networks (right fusiform and left parietal cortex107). By comparison, 389 
reduced frontal power, particularly in the high-alpha band, during quiet play at 3 months of age108 and 390 
cortical hyperexcitability in the right tempo-parietal region during auditory repetition of pure tones at 9–391 
10 months of age have been found in babies at familial risk for ASD109, suggesting that atypical patterns 392 
occur in brain regions other than those involved in social processing. Such alterations could have a 393 
cascading effect on social learning and contribute to the later emergence of behavioural symptoms of 394 
ASD, although a causal link remains to be demonstrated. Replications across different research centres 395 
are needed because many of these studies had small sample sizes, different definitions of groups and 396 
varied measures and time points.  397 
Interestingly, results from MEG and EEG studies jointly point toward two physiological mechanisms of 398 
ASD: excitation/inhibition (E/I) imbalance and alteration of large-scale functional interactions of brain 399 
systems as quantified through connectivity analysis110. An E/I imbalance is supported by results from 400 
computational modelling of how reductions in the amount of inhibition can account for the previously 401 
observed perceptual consequences of ASD111 and transcranial magnetic stimulation (TMS) studies 402 
demonstrating a neurophysiological deficit in γ-aminobutyric acid (GABA) receptor-mediated function in 403 
people with ASD112. In parallel, decreased long-range functional connectivity has also crystalized as a 404 
consistent mechanism113. MEG studies have especially suggested a complex functional connectivity 405 
pattern in the somatosensory cortex with reductions in the feedback (top-down) direction, but increased 406 
in the feed-forward (bottom-up) direction 114. Clarifying the extent to which this pattern is a 407 
methodological artifact that could result from the predominant average-brain approach, as suggested by 408 
fMRI studies, is critical115. 409 
Beyond use to understand the pathophysiology of ASD, the scalability and accessibility of EEG suggest that 410 





theory have already provided promising case-control classification116, but developing generalizable 412 
biomarkers may require a combination of multiple EEG measures supported by robust machine learning 413 
methods117. Against the background of the current reproducibility crisis that characterizes many 414 
studies118, as well as the defining heterogeneity of ASD, the next breakthrough will certainly demand large-415 
scale collaboration between researchers and clinicians. 416 
 417 
[H1] Diagnosis, screening and prevention  418 
Diagnosis of ASD is made on the basis of behavioural presentation. Although substantial heterogeneity 419 
exists between and within individuals across development, a set of core diagnostic features of ASD 420 
(covering social interaction, communication and flexible or sensory behaviour) can be reliably identified 421 
by trained clinicians119,120.  422 
[H2] Diagnostic criteria  423 
The re-formulation of the diagnostic criteria for ASD in the DSM-5 (Table 1)121, which is similar to the 424 
criteria in ICD-11122, contains several changes from previous editions that were based on good empirical 425 
and clinical evidence123. First, the sub-classification of ‘Asperger’s disorder’ was subsumed under the 426 
unitary term ASD as the diagnosis was inconsistently applied even by expert groups124. This change is 427 
controversial, but the evidence supporting the inclusion of Asperger’s disorder as a separate condition is 428 
very weak125 . The important questions are how better to consider the factors that characterize 429 
differences among autistic individuals and ensuring that these differences are measured and addressed 430 
using neurobiological and clinical research, rather than contained within very poorly defined categories 431 
of Asperger’s and PDD Not Otherwise Specified (NOS) as defined in DSM-IV. In addition, some individuals 432 
with social communication problems but not restricted and repetitive behaviours who would previously 433 
have fallen into the now-removed subcategory of PDD-NOS now receive a different diagnosis of Social 434 
communication disorder, which is not yet well-validated. Although these changes have led to concerns 435 
that the DSM-5 ASD criteria are more restrictive than those in DSM-IV, many clinicians feel that the 436 
changes better reflect clinical consensus and practice. Second, the social and communication domains of 437 
the diagnostic criteria were unified to reflect the factor structure of symptomatology. Third, sensory 438 
anomalies (hypersensory and hyposensory responsiveness and sensation-seeking) in DSM-5 were 439 
included under the ‘restricted, repetitive behaviours and interests’ domain to reflect their 440 
pervasiveness126. Fourth, the DSM-IV criteria required symptoms to be present in the first 3 years of life, 441 
but criteria in DSM-5 recognise symptom onset occurring in the early developmental period with the 442 
caveat that symptoms might not fully manifest until social demands exceed limited capacities. This change 443 
recognizes the developmental nature of ASD, wherein for some individuals, clear manifestation of ASD 444 
might not be apparent until mid-childhood, adolescence or even adulthood. In addition, late diagnosis 445 
(that is, diagnosis beyond early childhood) can occur even in those who received intensive early 446 
monitoring127. In addition, the DSM-5 criteria supports the use of specifiers that can denote those with a 447 
dual diagnoses, such as individuals with ASD and ADHD or other psychiatric disorders, as well genetic 448 





implications for large-scale data pooling efforts; for considering domains of behaviour to be modelled; 450 
and for identifying shared and distinct developmental pathways to conditions like ASD and ADHD.  451 
 452 
[H2] Diagnosis and screening in children  453 
The two core elements of the diagnostic process of ASD in children are a detailed developmental history 454 
that is usually obtained from parents, covering first concerns and early history to the present day, and an 455 
observation of the child’s interactions with their parents and with unfamiliar adults during a combination 456 
of structured and unstructured assessments. Ideally, observations of the young person in peer-group 457 
settings such as school or nursery would also form part of the diagnostic process. Of note, in one 458 
population-based study in the UK, girls with similar levels of symptom expression to boys were less likely 459 
to receive a diagnosis of ASD from clinical services 128. This finding might reflect socio-cultural factors in 460 
the application of the diagnostic criteria, greater resilience or protective factors in girls that reduce the 461 
need for clinical services at a given symptom level, or the need for the revision of instruments used to 462 
identify symptoms to more fully cover female autistic traits123  463 
A number of structured diagnostic interviews and observational assessments for ASD exist, but only a 464 
limited number have been rigorously tested for diagnostic accuracy relative to the gold-standard of expert 465 
clinician judgement. Although these interviews and assessments have reasonably robust sensitivity, 466 
specificity and reliability (see 129 for a review) and are widely used in some services in communities130, 467 
there are also challenges to the widespread adoption of the best validated instruments: the Autism 468 
Diagnostic Interview–Revised (ADI-R131) and the Autism Diagnostic Observation Schedule–2nd Edition 469 
(ADOS-2119). These challenges include the cost of the instruments and training, the time required to 470 
complete them and the need for substantial training to use them reliably132. Although expert clinical 471 
judgement was previously believed to be more reliable than reliance on instrument scores alone for the 472 
diagnosis of ASD133, more recent evidence suggests this may not be true at least in toddlers and preschool 473 
children 134. The need to take a global perspective on ASD is driving attempts to develop more scalable 474 
tools, but this work is currently in its infancy (Box 1)135.  475 
The stability of a diagnosis of ASD from the preschool years to mid-childhood is relatively high1. However, 476 
although diagnostic systems currently presuppose that ASD is a lifelong condition, there is a growing 477 
recognition that ASD has a heterogeneous developmental time course136. Indeed, sub-groups of 478 
individuals with ASD and improving or worsening symptoms over time can be identified 137,138. Such 479 
developmental trajectories might be a more meaningful phenotype on which to map aetiological 480 
mechanisms than a static case-control dichotomy70,139,140. Some individuals diagnosed as children have no 481 
clinically meaningful (or even detectable) impairment later in life (so-called ‘optimal outcome’141,142); one 482 
critical question in identifying mechanisms is whether this profile is associated with successful effects of 483 
early intervention or is an aetiologically distinct subtype of ASD.  484 
 [Au: please see the comment in the Epidemiology section (line 121) regarding the use of the term 485 
‘screening’ - do we need to introduce some edits here? I’d be grateful if you could take a look through 486 
this and amend as needed.] [H3] Screening and early identification. The potential for early testing to 487 
prospectively identify children with ASD at a young age has considerable interest, and several studies have 488 
evaluated the performance of parent-report instruments between 14 and 24 months of age, such as the 489 





examples added based on Tony’s comment YES fine] 129,143,144. However, there are contrasting views on 491 
the strength of the evidence for universal population-wide testing145,146. Of note, research is lacking on 492 
the effectiveness of therapeutic interventions in those identified with ASD through universal screening. In 493 
addition, although it is possible to identify some children with ASD before parents or professionals have 494 
identified concerns, diagnosis is missed in many children 147, and most tested cohorts have not been 495 
systematically followed up to identify later-onset ASD in children who initially tested negatively 148. 496 
Screening also often identifies children with broader developmental difficulties as well as those with 497 
ASD149. In general, such instruments could be more useful for identifying possible signs and symptoms of 498 
ASD in high-risk populations, for example in young children with older siblings with ASD150, or in those 499 
referred for speech or other developmental concerns to community paediatric services151. In addition, 500 
population-wide testing may also play a part in improving awareness and recognition of the early signs 501 
and symptoms of ASD in both professionals and the general public, which alongside ongoing 502 
developmental surveillance pathways in community services, could help to bring down the age of 503 
recognition and diagnosis. These principles also apply in low-income and middle-income countries in 504 
which testing for ASD and other neurodevelopmental disabilities has only just begun to be developed149. 505 
Very little research has been devoted to cultural and ethnic differences in either child early presentation 506 
and parents’ understanding or the experience of autism, which may in fact affect how screening 507 
instruments work and thus impact on parents and families as much as autistic individuals.  508 
 509 
 [H3] Early developmental profiles. Understanding of onset patterns of ASD has dramatically expanded 510 
over the past 10 years, through work on infants with a first degree relative with ASD, who due to the high 511 
heritability of the condition have a 20% chance of developing ASD themselves25. Symptoms of ASD have 512 
a gradual developmental onset. Indeed, although the average age of ASD diagnosis remains ~4–5 years of 513 
age152, parents typically report first concerns to health professionals at ~2 years of age 153. In many 514 
individuals, symptoms emerge during the second and third year of life (although, as per the DSM-5 onset 515 
criteria above, in others, onset might not be noticed until the child reaches school-age or later) whereas 516 
in others, symptoms become apparent after a seeming period of typical development, including a period 517 
of regression or stasis. To this end, conceptualization of what has been called ‘regression’ prior to 2 years 518 
of age has been reconsidered 154,155. Over the first two years of life, a substantial proportion of infants who 519 
later receive ASD diagnoses show gradually accumulating delays across social, communication and 520 
language domains, suggesting that ‘regression’ represents a spectrum ranging from frank loss of acquired 521 
skills, to a gradual erosion (or ‘plateauing’) of developmental potential to individuals in whom these skills 522 
never emerge 156. 523 
  524 
[H2] Diagnosis and screening in adults 525 
 Information on diagnostic methods to identify ASD in adulthood is in its infancy, with little 526 
methodologically acceptable evaluation of interview methods or screening questionnaires (including self-527 
completion questionnaires). Clinical approaches rely heavily on extending methods developed for use in 528 
childhood to adulthood. These methods tend to rely on childhood developmental data, although 529 
validation research in adult general population-wide testing suggests good specificity and sensitivity for 530 





judgment of expert clinicians and of standardized data collection on early child development that is 532 
unlikely to be obtainable for many older adults. Given that (undiagnosed) autistic adults presenting for an 533 
ASD assessment are also more likely to have co-occurring adult mental health disorders, any method of 534 
assessment must be capable of differentiating such abnormalities in symptoms and behaviour from 535 
abnormalities due to ASD. This point has led to the suggestion that clinical examination methods to 536 
identify adult psychopathology could be extended to include ASD in addition to depression, anxiety and 537 
psychosis, among other disorders158. Semi-structured adult psychopathology interviewing has been 538 
fruitful in the assessment of closely related neurodevelopmental disorders in adults, most notably 539 
ADHD159. Given that most people in the world who are autistic are adults , and as many of these individuals 540 
have not received a diagnosis of autism4,15 [Au: OK to add this text in based on Traolac’s comment? I’ve 541 
also added callouts to the relevant references here] , the development and evaluation of such adult 542 
assessment approaches is an urgent research priority.  543 
 544 
[H2] Co-occurring disorders  545 
In addition to the core features of ASD, co-occurring difficulties or disorders (Fig. 5) are much more widely 546 
recognized in research160,161, although they are not necessarily adequately addressed in clinical practice162. 547 
For preschool children with ASD, language delays, motor problems, epilepsy, difficulties with sleep and 548 
eating, and high levels of activity are most commonly observed 163,164. By comparison, ADHD, anxiety, 549 
obsessive-compulsive disorder (OCD), intellectual disability, academic challenges, irritability and 550 
disruptive behaviours become more apparent in school-aged children165. The proportion of individuals 551 
with depressive symptoms becomes higher in adolescents and adults166, whereas other issues often 552 
remain. Moreover, growing evidence (although it is reliant on administrative case-finding data) suggests 553 
that people with ASD have premature mortality 167,168 and increased risk of self-harm and possibly suicide, 554 
although the mechanisms involved have yet to be elucidated. Studies using electronic health records have 555 
demonstrated that adults with ASD are more likely to be diagnosed with many physical health conditions 556 
such as immune conditions, sleep disorders and obesity, compared with adults in the general population 557 
162.  558 
Collectively, these difficulties and disorders contribute to ASD severity169 and independence and well-559 
being at each age170 . However, it is important to note, in the context of heterogeneity, that the prevalence 560 
of each of these co-occurring conditions varies considerably with the context of the sample (such as from 561 
psychiatry referrals, neurological referrals, or schools) and the methodology used (administrative, self-562 
report or assessed), as well as with age, level of cognitive function and perhaps region161). As many of 563 
these conditions are treatable, they are very important as clinical considerations but are also more 564 
complex than sometimes conveyed. [Au: please ensure OCD is mentioned in this section as it is 565 
mentioned in management, below. Does it manifest in adults with ASD or during adolescents?] [Au: I 566 
can’t see this addition! Where was it added exactly? I have added above now…]  567 
 568 
[H1] Management 569 





Early intervention is seen as a priority because many young children with ASD struggle to communicate 571 
and interact with others, restricting their opportunities to learn and affecting their parents who can find 572 
their child’s behaviour perplexing and challenging to manage. Thus, outcomes of such interventions 573 
include changes in the individual’s availability for learning and increased parent understanding. 574 
Intervention delivered in the preschool years at an age when there is increased brain plasticity might lead 575 
to additional benefit, although this theory has not yet been empirically supported.  576 
The primary models of psychological intervention for preschool children with ASD are developmental and 577 
behavioural. Although some consensus has been reached on the interventions that have more supporting 578 
evidence (termed ‘naturalistic developmental behavioural interventions’171), there is some uncertainty 579 
and disagreement about the strength of evidence for different approaches, with almost no direct 580 
comparisons of treatments or studies to assess which child should receive what treatment or treatment 581 
intensity. Indeed, clinical trials in ASD are limited by cost, time, placebo effects and limited outcome 582 
measures, and are far behind much of the other research. This gap leaves parents and practitioners at the 583 
mercy of what is avaiable and sometimes marketed in their region. Indeed, access to early intervention 584 
services is variable in most communities, including in high-income countries, and is mostly carried out by 585 
non-specialists supervised by specially trained professionals. In low-income and middle-income countries, 586 
most children and young people with ASD — similar to those with intellectual and developmental 587 
disabilities — will not receive specialized services172, although a number of groups have begun to test 588 
community delivery of early intervention in such settings173.  589 
Many current interventions build on the original ‘Applied Behaviour Therapy’ 174(ABA) and have shifted to 590 
more natural, child-initiated developmentally appropriate strategies and tasks instead of dependence on 591 
repeated ‘discrete trials’ (known as discrete trial training, or DTT). In addition, considerable variation exists 592 
between different intervention models in terms of mode of delivery (for example, parent-mediated versus 593 
therapist-implemented), length (12-week versus 2-year programs), intensity (from a few hours a week to 594 
~15 hours per week) and the balance between the developmental or dyadic versus behavioural 595 
components.  596 
Lower-intensity approaches include parent-mediated interventions whereby parents are coached to 597 
become more attuned to their child’s communication signals and style (which are considered an 598 
intermediate child outcome) and to facilitate more joint engagement in play and everyday activities, 599 
designed to increase social and communication skills in the child175. Some studies have demonstrated 600 
enhanced joint engagement and joint attention (which are considered important intermediate child 601 
outcomes), with these lower-intensity approaches in preschool children compared to a control group, 602 
such as the 12-week Joint Attention Symbolic Play Engagement and Regulation (JASPER) program, both 603 
when delivered by parents in the home176 and by teaching assistants in school177. However, other lower-604 
intensity, time-limited parent-mediated interventions such as Focus Playtime Intervention (FPI)178 have 605 
not improved child outcomes (such as social orienting and joint attention), although some interventions 606 
have increased parental responsiveness179. A longer program (Preschool Autism Communication Trial 607 
(PACT)), which consists of fortnightly parent-therapist sessions for 6 months, then monthly sessions for 608 
another 6 months, demonstrated improvements in parent and child dyadic behaviours such as parental 609 
synchrony and child initiations when interacting with each other (those close to the intervention target) 610 
but not symptom reduction at immediate follow-up180. A subsequent 6-year follow-up to mid-childhood 611 
at age 7 to 11 years identified modest reductions in overall ASD symptoms using the ADOS over the whole 612 
course of the study that were not detectable at the immediate endpoint, suggesting that a longer-term 613 





A higher intensity, more comprehensive approach is the Early Start Denver Model (ESDM), which 615 
combines behavioural and developmental or dyadic approaches. The ESDM is delivered by therapists for 616 
~15 hours per week, and as part of this programme, parents are trained to improve social communication 617 
and interaction with their child. A small-scale trial demonstrated improvements in child developmental 618 
and adaptive outcomes, primarily in the language and communication domains, following 2 years of ESDM 619 
compared with treatment as usual182. One larger multi-site trial found attenuated benefits with 620 
improvement in language outcomes at two of the three trial sites, but no differences between the 621 
treatment as usual and ESDM groups in overall developmental ability, adaptive behaviour or ASD 622 
severity179,183.  623 
Many of these early intervention approaches are based on models of typical development. Increasingly, 624 
studies are using a combination of methods to define treatment outcomes and to better understand the 625 
mechanisms and models of change of interventions. These methods include analysis of the degree to 626 
which changes in the direct target of the intervention (for example, parent behaviour) mediate later 627 
changes in child behaviour181, and the use of experimental methods such as EEG to examine whether there 628 
are accompanying changes in relevant brain networks184. Many parents seek complementary medical 629 
approaches, which to date have not been supported and sometimes are dangerous185. A note of general 630 
caution is that even in the context of significant treatment differences between groups, individual 631 
outcomes are very variable, and some children do not improve, although reliable predictors of response 632 
to treatment have not been demonstrated in rigorous, randomized controlled trials. As ASD is a 633 
heterogeneous developmental condition, different interventions may be required at different stages 634 
throughout life and different individuals might benefit from different interventions [Au: edits for brevity 635 
ok? Yes] . One area which many consider to hold much promise, that of neurobiologically or biomarker 636 
‘informed’ psychological intervention, is on the horizon but such targeted therapies have not yet been 637 
developed.  638 
[H2] School age children and adolescents  639 
Many children and young people with ASD can also benefit from interventions at later ages. A number of 640 
programs and approaches are available that focus on the core social communication difficulties of ASD; 641 
for example, social skills training programs for which moderate evidence of benefit exists 186,187. In 642 
addition, non-verbal young people with ASD can benefit from use of augmentative communication 643 
systems, such as the Picture Exchange Communication System (PECS) that use picture symbols and 644 
behavioural training methods to allow children to request and make choices188 or other technology-based 645 
augmentative communication systems. Increasingly, more generic interventions that target co-occurring 646 
emotional and behavioural problems are being adapted for youths with ASD, and initial studies suggest 647 
moderate benefits189. These interventions include modified cognitive behavioural therapy (CBT) for 648 
anxiety (modified, for example, to include parents, increase the duration of sessions, use more visual 649 
materials and specific work on understanding one’s own emotion states) 190 and parent-mediated 650 
interventions for disruptive behaviour and ADHD191. More recently, there have been efforts to develop 651 
and test interventions that target aspects of parental wellbeing, such as parental stress and self-efficacy 652 
192. Increasingly, interventions for school-age children and young people with ASD are being delivered 653 
within the school environment, rather than the clinic, which has natural advantages for progammes that 654 
consist of groups or peer-to-peer interactions and an emphasis on social skills. Indeed, it is hoped that this 655 
approach may facilitate generalization of the skills learned193,194. 656 
  657 





As individuals with ASD progress into and through adulthood, the focus of management shifts from 659 
treating the core symptoms of ASD to addressing associated symptoms or behaviours and promoting 660 
independence. However, there are few intervention studies to guide treatment options in adulthood. 661 
Indeed, a 2012 systematic review identified only 32 studies published between 1980 and 2010 that 662 
evaluated treatment studies for adolescents and young adults with ASD195. A more recent review 663 
identified 41 studies of interventions targeting social functioning in adults over a 37-year period196.  664 
Despite the low number of treatment studies, there is some evidence supporting treatment efficacy for a 665 
limited number of symptoms, behaviors, and functional outcomes such as employment, social skills, and 666 
anxiety; however, in general, the evidence-base is weak195,196. For example, only three randomized 667 
controlled trials (all of which included small cohort sizes) that tested job interviewing skills curricula have 668 
been published. Social skills interventions have a somewhat more robust literature base (see 196 for 669 
review), but most of these studies had very small sample sizes and were not well controlled. In addition, 670 
it is unclear whether social skills interventions can be generalized to other social settings and situations, 671 
that is, whether skills learned in the treatment context are used by the participants in other settings, such 672 
as with peers or at work. There is some evidence for the use of cognitive-behavioural therapy (CBT) for 673 
effectively treating anxiety in people with ASD who do not have cognitive delays or language problems 674 
[Au:OK to add in this highlighted text? This was mentioned in the now-deleted ‘Treatments for anxiety’ 675 
section] 197. However, nearly all of the existing research has been conducted with children and adolescents 676 
rather than in adults196, and individuals with substantial communication challenges are excluded from CBT 677 
studies. Furthermore, in contrast to the general population, CBT has not yet been shown to be effective 678 
for the treatment of depression in individuals with ASD. Given this weak evidence base, it may be fruitful 679 
to explore therapies and treatments tested in other groups that may benefit those with ASD.  680 
Formal service systems and social care can help fill in the treatment gaps. Indeed, although many adults 681 
with ASD do not receive adequate services and support198, their receipt can improve outcomes across a 682 
number of domains 158. For example, transportation services can allow adults with ASD to engage in 683 
employment and access therapies and programs in the community. In addition, comprehensive job 684 
support services can promote finding and maintaining employment, particularly for adults with more 685 
severe impairments 199. Public health insurance can increase access to psychiatric care for those with co-686 
occurring mental health problems, and income supports can reduce dependence on families.  687 
 688 
[H2] Medications  689 
All medications that have evidence of benefit for ASD treat the associated symptoms or co-occurring 690 
diagnoses, rather than the symptoms of ASD directly ( including social communication or repetitive 691 
behaviours). As mentioned earlier, ASD is an extremely heterogeneous disorder, and individuals with ASD 692 
can have a number of common co-occurring disorders that can also vary in severity.  693 
Risperidone and aripiprazole (both of which are atypical antipsychotics) are approved in the USA to treat 694 
irritability and agitation — including aggression, self-injury and tantrums — in children and adolescents 695 
with ASD200–202. However, both treatments are associated with adverse events, including sedation, risk of 696 
movement disorders and weight gain, which limit their use to people with severe irritability with 697 
agitation202. The anti-diabetes drug metformin has been shown to limit weight gain from these 698 





As mentioned previously (see Co-occurring disorders, above), co-occurring mental health conditions are 700 
common in people with ASD. Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD 701 
symptoms in ASD (Table 2 204–206) [Au: given that these medications target different symptoms of ADHD 702 
are they ever prescribed in combination? Or will a child be given one medication only?] . Although 703 
serotonin reuptake inhibitors (SRIs), such as fluoxetine and citalopram, are used for the treatment of 704 
depression, anxiety and OCD in the general population, they have differing efficacy in people with ASD 705 
[Au:OK?] . Indeed, although fluoxetine improves symptoms [Au: all symptoms?] of OCD in adults with 706 
ASD207, citalopram has demonstrated poor tolerability and no benefit for repetitive behaviour in children 707 
with ASD208. Medications for depression or anxiety have not systematically been tested in people with 708 
ASD. 709 
 [Au: as this text is very future-looking, would it be best placed in the Outlook section?] Some excitement 710 
has accompanied the recent studies of medications targeting the neurohormonal oxytocin or vasopressin 711 
systems, both of which modulates social behaviour across species. Underpowered studies of intranasal 712 
oxytocin have demonstrated mixed results that are overall not supportive of a large effect size209,210, with 713 
results pending from adequately powered studies [Au: please provide the NCT number of this ongoing 714 
study here so readers can follow up in due course] . In addition, a pilot study of intranasal vasopressin 715 
suggested possible benefit in people with ASD, although this study was underpowered211. A large trial of 716 
balovaptan, a vasopressin AVPR1A antagonist in adults with ASD showed negative results on its primary 717 
outcome ( a general rating of ASD symptoms), with suggestive results on a key secondary parent report 718 
measure of adaptive behaviour, including social and communication behaviour 212. A few studies have also 719 
focused on the hypothesis that, at the level of neural circuits, ASD may result from excessive excitation or 720 
insufficient inhibition 213, with some promising but inconclusive results for medicines that target the 721 
GABAergic system 214. Medications targeting genetic syndromes that can cause [Au:OK?] ASD have not 722 
yet yielded consistent improvement215,216, but there is much hope for a precision medicine approach that 723 
links genetic subgroups with neurobiology-based treatments. 724 
 725 
[H1] Quality of life 726 
[H2] Objective and subjective measures 727 
Several aspects of intervention research speak straight to the heart of current debates within the clinical 728 
field and broader ASD community, including how a good outcome is classified for an individual with ASD, 729 
as well as who should decide what outcomes are used [Au: edits for style ok?] in intervention studies217. 730 
This point is aligned both with the debates about medical versus social models of disability but also with 731 
a more general shift in medicine away from focusing on symptom reduction to improving the wellbeing 732 
and quality of life (QOL) of patients. QOL research in adults with ASD has focused on two aspects: objective 733 
and subjective QOL. Objective QOL encompasses social achievements such as employment, adequate 734 
living conditions, supportive relationships, and good physical and mental health218, whereas subjective 735 
QOL focuses on individuals’ perceptions and subjective assessments of their own lives219. Both subjective 736 
and objective QOL are often related, but not synonymous, and both are important to take into account 737 





[H3] Objective QOL. Adults with ASD tend to have poor objective QOL. Unemployment is high in this 739 
population, and even among those employed, individuals are often working below their skills and 740 
abilities220,221. Moreover, independent living can be [Au:OK? As presumably some individuals may be able 741 
to live independently with relative ease?] a challenge, and adults often lack meaningful relationships 742 
with peers222. When aggregating across these domains of life, many adults with ASD have ‘poor’ or ‘very 743 
poor’ outcomes223,224.  744 
ASD is a highly heterogeneous condition and several factors have been associated with higher versus 745 
lower objective QOL. Most of the studied factors associated with higher objective QOL have been 746 
characteristics of the individuals (versus families, service system or communities), and consistent 747 
predictors of higher objective QOL include better early language development [Au:OK?] , higher IQ and 748 
adaptive behaviour scores, less severe ASD symptoms, and fewer challenging behaviours 225. In addition, 749 
more recent research suggests that women with ASD may have a more difficult time maintaining 750 
employment positions226, and are more likely to ‘camouflage’ their ASD symptoms than men, which can 751 
lead to mental health challenges227. 752 
 [H3] Subjective QOL. Meta-analysis have suggested that across the lifespan, subjective QOL tends to be 753 
lower among individuals with ASD compared to typically-developing peers228, but is often more positive 754 
than indicators of objective QOL223,229. Predictors of subjective QOL tend to be inconsistent across studies, 755 
except for perceived stress and supports, the latter of which encompasses services, family and social 756 
support 230–232.  757 
  758 
[H2] Self-advocate perspective 759 
 [Peer reviewer comment: The self-advocate perspective is important. It was quite noticeable to use 760 
identity-first language (“autistic people”) only in this section and some explicit reference to this choice 761 
might be made, to help readers understand the politics and differing viewpoints.] It is clear that ASD has 762 
heterogeneous outcomes and biological underpinnings; what is less clear-cut are the differing and 763 
nuanced views of autistic people regarding how ASD should be approached and researched (Box 2, 764 
Autistica233, see also Ontario Brain Institute234). Indeed, some people with a diagnosis see ASD as being a 765 
fundamental part of their identity whereas other people do not. In addition, many people feel that social 766 
change is required235, whereas other individuals want therapies to meet a range of their needs236. The key 767 
is respect for a variety of views and ultimately respect for autistic people. Researchers can demonstrate 768 
respect by considering how ASD as a topic is distinct from, for example, cancer. To this end, terms like 769 
‘disease’ are inappropriate and are scientifically inaccurate when referring to ASD. Ultimately, active 770 
participation in the design, implementation and interpretation of research studies [Au:OK?] , clear 771 
consideration of research ethics and the consequences of research involvement, and broad consultation 772 
of autistic people in research is key to authentically addressing the substantial inequalities autistic people 773 
face as a group and ensuring they live long, healthy, happy lives. 774 
 775 
[H2] Family perspectives 776 
Families of people with ASD are also heterogeneous, yet, as a group, they experience lower QOL than 777 
families with a member with other neurodevelopmental conditions, even before receiving the formal 778 





the entire external support system coalesce around common goals for outcomes whilst accessing and 780 
maximizing resources for the betterment of the child and family. Parents are typically at the centre of this 781 
support network and carry much of the responsibility of direct care, coordination and advocacy, over and 782 
above typical parental responsibilities238,239. The exact parental roles are dependent on the child’s 783 
strengths and challenges, and frequently shift over time (Fig. 6). During this process, it is important that 784 
parents maintain motivation by setting realistic goals and tracking progress to experience the many 785 
achievements that their loved one with ASD can attain.  786 
Effective parents often work closely with experienced providers who can track development of the child 787 
with ASD and can provide guidance on next actions240. Early in childhood [Au:OK?] , this role includes 788 
identifying and engaging with early and school-based interventions. It is never too early for parents to 789 
begin planning for the adult transition process, including (dependent on the person with ASD’s capacity) 790 
promoting self-advocacy, preparation for life after secondary education, vocational training and 791 
employment supports, living needs, community participation, and long-term financial considerations. 792 
During adulthood, for cognitively-able adults, parental roles might shift to more traditional 793 
relationships241, whereas for those with cognitive disability, parental caregiving often continues and 794 
culminates in planning for late life needs242. Although the journey can be challenging, for many parents, it 795 
can be incredibly rewarding and a source of life meaning. 796 
Many parents recognize the need to give back to the community [Au:OK?] through research. Accordingly, 797 
it is crucial that researchers foster this desire carefully, communicating with parents to ensure that any 798 
potential immediate or future risks or benefits are clear. Even if the study period is brief, in many cases, 799 
the goal should be to develop a positive longer-term relationship, as this can lead to parents and people 800 
with ASD continually re-engaging in and developing positive feelings about the research process. 801 
[H1] Outlook 802 
ASD research has substantially expanded in the past 50 years, particularly the past 20 years, as reflected 803 
in the websites listed in Box 3. Although it seems unilikely that the incidence of ASD is truly rising at the 804 
rate suggested in prevalence studies, these data have increased awareness and the numbers of diagnosed 805 
children in schools and clinics, although adult services and recognition run far behind. The lives of people 806 
with ASD diagnoses have improved at least in some high-income countries, with a greater proportion of 807 
children using some language243, more adults with educational qualifications and less 808 
institutionalization243, although the changing nature of diagnoses has to be considered when interpreting 809 
historical trends. Some risk factors for ASD have been identified (such as increased parental age, birth 810 
trauma and a positive family history) which has implications at least for more careful follow-up. In 811 
addition, the genetics of ASD has yielded surprising discoveries with substantial implications for heritable 812 
neurodevelopmental disorders, such as ADHD, language delay and named syndromes associated with 813 
profound intellectual disability. The perceived value of routine genetic screening for ASD diagnosis is 814 
disputed,  [Au: edits ok?] , with American medical academies strongly in favor whereas those in other 815 
countries much more selective. Studies of brain structure and function have added similarly intriguing 816 
findings that are just beginning to be integrated into both developmental and more mechanistic models 817 
of behaviour with possible targets or markers for change. Despite the intellectual contribution of these 818 
studies to research, at this point, neither EEG nor imaging are recommended as part of standard practice 819 
for diagnosis of  [Au:OK?] ASD but can be used  for other neurological indicators (such as if there are 820 





sites and even within individuals, as well as larger samples through collaboration are the promise of the 822 
future.  823 
One way of bringing the three themes of mechanisms, heterogeneity and outcomes of ASD together is to 824 
consider the trajectories of this disorder over time (Fig. 7), and how knowledge of these trajectories can 825 
contribute to investigations of the biological and cognitive underpinnings of ASD, and how treatments and 826 
supports could make the lives of chidlren and adults with ASD more positive.  827 
In terms of mechanisms, despite earlier hopes for simple genetic explanations of ASD, instead, we have 828 
identified many single gene germline loss of function point mutations yielding some initial models of 829 
disruption in very basic molecular patterns, as well common genes with small effects that are just 830 
beginning to emerge29. Attempts to study genes-first have shown heterogeneity even within highly 831 
specific CNVs, with a few exceptions. In addition, hope exists that genetically based interventions for ASD 832 
may be possible, although this will likely involve much further research . [Au: please advise how to 833 
proceed here - would you like to move this text back?] Indeed, given the success and approval of gene 834 
therapy for early onset neurological disorders, particularly spinal muscular atrophy (SMA) type 1244,245, 835 
targeting single genes of large effect in both idiopathic and  836 
monogenic ASD is being viewed as increasingly plausible.  As rare syndromes such as fragile X syndrome, 837 
angelman syndrome and rett syndrome have offered some of the earliest insights into ASD biology, these 838 
disorders are also likely to lead the way in illuminating the practical and important ethical challenges that 839 
will attend such efforts for idiopathic ASD. Efforts aimed at the highest confidence risk genes identified in 840 
idiopathic ASD, such as SCN2A and CHD8 34,35, are almost certain to soon follow on attempts at gene 841 
therapy for monogenic neurodevelopmental disorders, in light of the growing list of well-defined large-842 
effect targets, the increasing options for addressing haploinsufficiency246, the ability to manipulate gene 843 
products without leaving a DNA “scar”246,247 and the increasing ability to readily detect mutations—and 844 
intervene—in utero and very early in post-natal development. 845 
Data from genetic approaches that might yield targeted genetic interventions may be most relevant to 846 
rare, severe neurodevelopmental difficulties in general rather than ASD as a specific entity. With more 847 
information about the differing developmental trajectories of ASD, more continuous measures of 848 
symptoms and measures of language and intellectual function, behavioural phenotypes and changes over 849 
time can be quantified across different neurobiologically defined subgroups. This approach could 850 
potentially identify different ‘routes’ to different outcomes, whether ASD or not, and could have a 851 
practical benefit in terms of selecting and monitoring appropriate treatments. In addition, with the 852 
heterogeneity of ASD, our growing understanding of mechanisms, be they causal or mechanisms for 853 
change, needs to be linked to trajectories in development and not be considered as static248 . Researchers 854 
modelling ASD in other species might find the incorporation of early developmental manifestations, such 855 
as regressions or motor delays, more tractable than the current focus on ASD- related social 856 
communication symptoms seen in humans. With collaborations and studies of sufficient sample sizes, 857 
investigators have begun to focus on findings within different developmental periods that could provide 858 
insight into trajectories and targets for intervention. Thus, more study of the development of ASD both in 859 
studies of human behaviours and in animal models might have an effect on the identification and 860 
treatment of ASD as a neurodevelopmental disorder. Prospective studies, including epidemiological and 861 
direct behavioural work across developmental periods, moving beyond very young children to later 862 





Similarly, limited findings about adult development and patterns that lead into ASD (Figs 5 and 7), call for 864 
measurement of different outcomes that respect individual differences in autistic people and in families 865 
(Box 2). By young adulthood, available supports for places to live, employment and mental health services 866 
are needed for individuals who have a range of skill levels, with supports not always well matched to the 867 
needs of individuals; however, comparisons of treatments or treatment intensities have not historically 868 
been made, even though they are continually called for. The types and specific goals of treatments differ 869 
greatly for autistic people who are verbally fluent versus those who have difficulty speaking for 870 
themselves, such that alternative systems need to be in place that take into account co-occurring 871 
conditions, strengths, preferences and challenges. More studies of well-defined, more homogeneous 872 
subgroups of autistic children and adults over time would provide different and more useful information 873 
about real-life issues, as in Table 3than large-scale surveys of very heterogeneous samples 249.  874 
Progress in the biology of more generally defined neurodevelopmental disorders may have the greatest 875 
yield for children with ASD in their early years [Au: compared with what? In their later years?] . Clinical 876 
trials that compare known treatments (both psychosocial and biological), with new ones and treatment 877 
as usual would allow us to build on previous findings in a more meaningful way and begin to address the 878 
priorities listed in Box 2 , which strikingly, are seldom priorities in autism research. To move from science 879 
to practice including evaluation and treatment, ASD researchers need to find a way to select and fund 880 
studies of more mundane, but critical evidence gaps in understanding heterogeneity, mechanisms of 881 
change and outcome that affect practice in any circumstance, not just internationally, within academic 882 
systems that reward creativity and novelty. Unique methodologies, including the baby sibling studies, 883 
accumulation of large data sets (such as ABIDE, and the Simons Simplex Collection (SSC)), prospective 884 
epidemiological studies and mechanistic studies of intermediate biomarkers may begin to bring together 885 
information from molecular to pathophysiological to cognitive and behavioural levels. However, for now, 886 
as for other neurodevelopmental and psychiatric disorders including schizophrenia250, the distance 887 
between science and practice remains great, and the amount of research that attempts to address 888 
solvable problems for autistic people alive today and their families remains modest.  889 
 890 





Box 1. Global challenges in autism research 892 
Recently, there have been calls for more attention to global issues in autism research249 (Global 893 
Research on Developmental Disabilities Collaboration – Lancet Global Health, 2016), including a number 894 
of related issues with somewhat different potential solutions. For example [Au: edits to improve the 895 
narrative flow ok?] , broader populations should be included in autism research, including individuals 896 
from Lower Resource and Middle Income countries (LMICs), but also inclusive representation of the 897 
ethnic, linguistic and socio-economic diversity of many High Resource  countries and people whose 898 
autism is unrecognised. Moreover, there should be the creation of opportunities to carry out research in 899 
LMICs 251(Patel et al, 2015). Open source and shared databanks, including autism-specific resources such 900 
as the Simons Simplex Collection and Autism Brain Imaging Data Exchange [Au:OK?] (ABIDE), as well as 901 
broader collaborations such as PsychENCODE [Au:OK?] could assist in promoting international research 902 
[Au: edits for brevity ok?] . In addition, the science of autism should be disseminated in ways that are 903 
useful for practice in all countries, [Au: edits ok?] but with particular attention to the needs of 904 
communities and families with fewer resources 252 253.  [Au: sentence deleted as suggested] More 905 
immediately, searches for scalable methods of identification and perhaps intervention with children and 906 
adults [Au:OK? Yes] with autism135,254 have begun [Au: globally or in LMICs?] . However, the need to 907 
develop scalable global practices highlights how little is known about when we need population-wide 908 
testing for autism versus broader neurodevelopmental disorders, the minimal intensity and duration of 909 
effective interventions, behavioural mechanisms behind changes in behaviour and which treatments 910 
work with which children and adults and families, all of which have a bearing on interventions locally 911 
and globally. In addition, global issues of stigma, governance and paucity of resources also have to be 912 
taken into account 251.  913 
 914 





Box 2. Top ten questions for ASD research proposed by autistic people, family members and 916 
professionals. (Reference: Autistica233)  917 
1. Which interventions improve mental health or reduce mental health problems in people with 918 
autism spectrum disorder (ASD)? How should mental health interventions be adapted for the 919 
needs of people with ASD? 920 
2. Which interventions are effective in the development of communication and language skills in 921 
ASD? 922 
3. What are the most effective ways to support or  [Au:OK? Our style is to avoid solidus as the 923 
meaning can be ambiguous] provide social care for autistic adults? 924 
4. Which interventions reduce anxiety in autistic people? 925 
5. Which environment supports are most appropriate in terms of achieving the best education, life 926 
and  [Au:OK?] social skills outcomes in autistic people? 927 
6. How can parents and family members be supported and/or educated to care for and better 928 
understand an autistic relative? 929 
7. How can ASD diagnostic criteria be made more relevant for the adult population? And how do we 930 
ensure that autistic adults are appropriately diagnosed? 931 
8. How can we encourage employers to apply person centred interventions and support to help 932 
autistic people maximize their potential and performance in the workplace? 933 
9. How can sensory processing in ASD be better understood? 934 
10. How should service delivery for autistic people be improved and adapted in order to meet their 935 
needs? 936 
 937 





Box 3. Examples of ASD websites [Au: based on Tony’s comment I’ve introduced some broader headings 939 
here rather than adding a description under each individual website - what do you think? Please check 940 
carefully and let me know if you prefer the original version (we can revert the changes, no problem!)]  941 
Sites for health care professionals or research scientists: 942 
[H1] American Academy of Pediatrics 943 
https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Pages/autism-initiatives.aspx 944 
 945 




[H1] National Autistic Society 950 
https://www.autism.org.uk 951 
 952 
[H1] Royal College of General Practitioners 953 
https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/asd-toolkit.aspx 954 
 955 
Information about treatment, research and advocacy for people with ASD and their families: 956 
 [H1] Autism Canada 957 
https://autismcanada.org 958 
 959 
[H1] Research Autism 960 
http://www.researchautism.net/  961 
 962 
[H1] Autism Europe 963 
https://www.autismeurope.org/  964 
 965 




[H1] WHO 970 
https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders 971 
 [H1] Autism Spain 972 
http://www.autismo.org.es 973 
 974 
[H1] Autism Speaks 975 
www.autismspeaks.org 976 
 977 
[H1] Autismus Deutschland  978 
https://www.autismus.de 979 
 980 
[H1] Autistica 981 
https://www.autistica.org.uk 982 
 983 






Information about research funding, and up-to-date information for people with ASD and families: 986 
 987 
[H1] Simons Foundation 988 
https://www.sfari.org 989 
 990 
 [H1] US NIH 991 
https://www.nimh.nih.gov/health/topics/autism-spectrum-disorders-asd/index.shtml 992 
[H1] Autism Science Foundation 993 
https://autismsciencefoundation.org 994 
 995 
  996 
Epidemiological information [Au:OK?]  997 




Figure 1. Theories and findings regarding ASD mechanisms, outcomes and heterogeneity.  1002 
 Original descriptions of the cardinal features of autism spectrum disorder (ASD) were attributed to a 1003 
range of causes including being raised by wolves (the Wild Boy of Aveyron), inborn limitations in affective 1004 
contact and unfeeling parenting (such as ‘refrigerator mothers’) and holy people (such as fools for Christ)) 1005 
255. Conceptualizations of ASD as a common highly heritable neurodevelopmental disorder with 1006 
underlying cognitive features began with the recognition of differences in brain function and cognition in 1007 
the 1960s256–259 and the first twin study in the 1970s260. Other proposed mechanisms include maturational 1008 
lags in neurophysiology90 andcognitive mechanisms such as joint engagement 171,261. With the search for 1009 
pathways to and sometimes out of ASD 262 on many levels, conceptualization of positive outcomes has 1010 
been more recent, but has also varied markedly. In the 1970s, autism societies and collaborative clinical 1011 
programs focused on community integration and de-institutionalization (such as National Autistic Society 1012 
(NAS) and National Society for Autistic Children (NSAC))263. Priorities shifted in the 1980s and 1990s, with 1013 
still unreplicated claims of ‘recovery’ in children who participated in intensive behavioural 1014 
interventions174, new advocacy groups focusing on biomedical discoveries to yield potential biological 1015 
treatments and even ‘cures’ (such as National Alliance for Autism Research (NAAR) and Cure Autism 1016 
Now255) and the neurodiversity movement264 which rejected ‘cures’ and called for adaptation of 1017 
environments to support autistic people, using terminology preferred by self-advocates and community 1018 
participation. Recognition of the marked heterogeneity within ASD began in the 1970’s with the triad of 1019 
impairments in language, play and social interaction characterizing many children with intellectual 1020 
disabilities (ID) or those with classical autism265. The first twin study demonstrated that monozygotic twin 1021 
pairs, though concordant for difficulties associated with ASD, differed in specific characteristics and co-1022 
occurring conditions including ID 260. More recently, phenotypic heterogeneity has been the rule in most, 1023 
though not all, gene-first phenotypic studies266. Thus, developmental aspects of differences in strengths, 1024 
difficulties and trajectories, as well as biological factors, require highly personalized conceptualizations of 1025 
the needs of autistic individuals and their families. ABA, applied behaviour analysis; AGRE, Autism Genetic 1026 
Resource Exchange; CDC, US Centers for Disease Control and Prevention; DSM, Diagnostic and Statistical 1027 





Syndrome Partnership ;IDEA, Individuals with Disabilities Education Act; MCEP, the gene associated with 1029 
Rett Syndrome; PACT, Preschool Autism Communication Trial; PDD, pervasive developmental disorder; 1030 
SNAP, Special Needs and Autism Project; SPARK, Simons Foundation Powering Autism Research for 1031 
Knowledge, TEACCH, Treatment and Education of Autistic and Communication related handicapped 1032 
Children. 1033 
 1034 
Figure 2. Environmental risk factors for ASD.  1035 
Data from studies aiming to identify risk factors for autism spectrum disorder (ASD) can be broadly split 1036 
into three categories, those with evidence supporting an association (panel a), those with inconclusive 1037 
evidence (panel b) and importantly, those with no supporting evidence (panel c). Bars represent ranges. 1038 
*Represents recurrence risk. Figure adapted from 18 with added findings from select reviews and empirical 1039 
papers: neonatal hypoxia estimate267, childhood vaccines20, valporate use during pregnancy268, parent age 1040 
estimates269, preterm birth estimate270,271, maternal obesity estimate272, folic acid intake estimate273, 1041 
siblings estimate274,275, interpregnancy interval estimate276, assisted reproductive technologies 1042 
estimate277,278, pesticide and air pollution estimate279, caesarian section estimate280.  1043 
 1044 
Figure 3. Encoded proteins associated with ASD risk. [Au: please ensure this figure is added to the third 1045 
party rights table and we will obtain permission to reuse it on your behalf. Note that I’ve added the 1046 
protein names in after the ASD syndromic genes, below ] 1047 
Simplified schematic of the major cellular components of a neural circuit in the cerebral cortex, with a 1048 
focus on pyramid-shaped glutamatergic excitatory projection neurons. Proteins encoded by selected high-1049 
confidence (FDR < 0.1) autism spectrum disorder (ASD) risk genes34 and proteins encoded by selected 1050 
syndromic ASD genes have a role in these neurons during development. These proteins have a diverse 1051 
intracellular distribution; those at the synapse, have roles in cell adhesion, scaffolding and signalling. In 1052 
addition, some of these proteins are localized to the nucleus and have been shown, broadly, to mediate 1053 
chromatin modification and transcriptional control. Syndromic ASD genes include FMR1 (encoding fragile 1054 
X mental retardation protein; fragile X syndrome), UBE3A (encoding Ubiquitin-protein ligase E3A; 1055 
Angelman syndrome), TSC1 and TSC2 (encoding hamartin and tuberin; tuberous sclerosis complex), PTEN 1056 
(encoding Phosphatase and tensin homolog) and MECP2 (encoding methyl-CpG-binding protein 2; Rett 1057 
syndrome). Adapted from 48. 1058 
 1059 
Figure 4. Longitudinal trajectories of total brain volume, surface area and cortical thickness in ASD.  1060 
[Au: please ensure this figure is added to the third party rights table and we will obtain permission to 1061 
reuse it on your behalf] Brain trajectories from 6–24 months of age for total brain volume (TBV, panel 1062 
a), surface area (SA, panel b) and cortical thickness (CT, panel c). [Au: These data are quite complex and 1063 
may be difficult for non-experts to understand; accordingly, please briefly describe the key trends in 1064 
this figure in 2-3 sentences, what are the take-home messages from the figure?] Corrected age [Au: 1065 
edited Length-age to ‘corrected age’ as per the original figure, ok?] refers to the age corrected by 1066 






Figure 5. Co-occurring disorders [Au: this title was too long to adhere to our production guidelines so 1069 
I’ve edited it down, ok? I’ve tried to incorporate the original title into the first line of the legend, is this 1070 
ok?] .  1071 
Primary and secondary disorders and disadvantage can accumulate through development in people with 1072 
autism spectrum disorder (ASD). These disorders can form additional targets for treatment and policy. 1073 
Prevalence [Au:OK?] estimates from QUEST281 SNAP133,282 and EDX142 cohorts [Au: please advise on how 1074 
to proceed with Terry’s comment here] . 1075 
 1076 
Figure 6. Major parental milestones in advocating and supporting their child with ASD.  1077 
Families of children and adults with autism spectrum disorder (ASD) have many decisions and 1078 
expectations across the lifespan of their children, from seeking initial diagnostic evaluation and 1079 
intervention to preparing for aging-related services. These decisions [Au:OK?] vary across different 1080 
cultures, regions and countries and depend on many factors, including the resources and services 1081 
available. However, several decisions are common across all regions [Au:OK?] , including LMR [Au: please 1082 
define LMR - do you mean LMICs?], such as choices about who will care for their child if the parents are 1083 
temporarily unable [Au: edits for brevity ok?] , the amount of time parents and other family members 1084 
can spend with the child with ASD versus meeting other needs, ways to modify their home environment 1085 
to ensure the safety and independence of the individual with ASD and the kinds of behavioural 1086 
expectations that are most helpful for their child or adult. Of note, for many families, these choices and 1087 
responsibilities are lifelong and are relevant, for children, adolescents [Au:OK?] , adults and elders 1088 
[Au:OK?] with ASD.  1089 
 1090 
Figure 7. Changes in daily living scores as predicted by IQ scores and autistic symptoms.  1091 
Changes in independent daily living skills can be observed in people with ASD over time. This sample 1092 
consists of ~100 young adults with a mean age of 26 years with autism spectrum disorder (ASD), who were 1093 
evaluated at 2, 3 and 9 years of age and followed up to 26 years of age.  [Au: I’ve incorporated the 1094 
discussion of how these scores were obtained and what they mean below (highlighted in yellow) for 1095 
flow, ok? Text discussing divergence and heterogeneity moved to later on in the legend for flow] Daily 1096 
living scores [Au: instead of ‘outcomes’, ok?] are very diverse, ranging from age-appropriate levels of 1097 
independence at adulthood (represented by a daily living score of 100 , assessed using the Vineland II283 1098 
[Au:OK?] ) to very limited skills (represented by a score of <30). [Au: green text moved to here from 1099 
earlier on for flow] Increasing divergence shows where measurement after 2 years of age is additionally 1100 
predictive, with the line thickness indicating the proportion of early referred children that followed each 1101 
trajectory. Heterogeneity in intellectual functioning and severity of ASD symptoms (social communication 1102 
and restricted, repetitive, sensory behaviors) can be observed. In addition, improvements and worsening 1103 
of autistic symptoms and intellectual functioning can occur over time. A, B| Referred children had verbal 1104 
IQs predominantly <50 (over 3 standard deviations below average) but could show improvement in daily 1105 
living standard scores [Au:OK?] from 2 to 3 years of age that were indicative of eventual greater 1106 





adulthood the association with eventual adult daily living skills is strong. C, D | Variation in ASD symptom 1108 
severity in social-communication (CSS refers to The Autism Diagnostic Observation Schedule, Second 1109 
Edition (ADOS-2) Comparison Scores) showed a stronger association with adult independence than 1110 
restricted-repetitive behaviours and continued to change over the lifespan following more divergent 1111 
pathways than intellectual functioning. Data from the EDX cohort compiled from 1,142,284. 1112 





Table 1: ASD as defined in DSM-5. 1114 
 [Au: I do think this version is improved, however, we can no longer include bullet points within tables 1115 
as this leads to problems at the layout stage - what about converting this to a text box (see example 1116 
below)]  1117 
  1118 
Domains Other criteria 
A. Social communication and 
social interaction 
B. Restricted, repetitive 
behaviours and interests 
Must have evidence across 
multiple contexts of all 3 
subdomains currently or by 
history 
Must have evidence of 2 of 4 
subdomains currently or by 
history 
C. Symptoms must be present in early 
development but may not be fully 
manifest until later or may be masked 
later in life by learned strategies 
Subdomains Subdomains D. Symptoms must cause clinically 
significant impairment in current 
functioning • Social reciprocity 
• Nonverbal communication 
Developing, maintaining and 
understanding relationships 
• Stereotyped, repetitive 
behaviours 
• Insistence on sameness 
• Highly restricted, fixed 
interests 
Hyper- or hyposensitivity or 
interest in sensory inputs 
Note: Previously established 
DSM-IV diagnoses of any 
pervasive developmental 
disorder, including Asperger’s 
disorder should be assumed to be 
equivalent to DSM-5 ASD 
Note: ASD may co-occur with 
many other disorders including 
ADHD, intellectual disability, 
language delay and genetic 
syndromes 
E. Not better explained by intellectual 
disability or global developmental delay 
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; DSM-5, Diagnostic and 1119 
Statistical Manual of Mental disorders, Fifth Edition.  1120 
 1121 
 1122 
Box xx. ASD as defined in DSM-5.  1123 
The Diagnostic and Statistical Manual of Mental disorders, Fifth Edition (DSM-5) criteria for autism 1124 
spectrum disorder (ASD) comprise 5 symptom clusters (A-E) 1125 
A. Social communication and social interaction. 1126 
• Must have evidence across multiple contexts of all of the following 3 subdomains currently or by 1127 
history 1128 
o Social reciprocity 1129 





o Developing, maintaining and understanding relationships 1131 
 1132 
B. Restricted, repetitive behaviours and interests. 1133 
• Must have evidence of 2 of 4 of the following subdomains currently or by history 1134 
o Stereotyped, repetitive behaviours 1135 
o Insistence on sameness 1136 
o Highly restricted, fixed interests 1137 
o Hyper- or hyposensitivity or interest in sensory inputs 1138 
 1139 
C. Symptoms must be present in early development but may not be fully manifest until later or may be 1140 
masked later in life by learned strategies 1141 
 1142 
D. Symptoms must cause clinically significant impairment in current functioning 1143 
 1144 
E. Not better explained by intellectual disability or global developmental delay 1145 
 1146 
Note: Previously established DSM-IV diagnoses of any pervasive developmental disorder, including 1147 
Asperger’s disorder should be assumed to be equivalent to DSM-5 ASD. ASD may co-occur with many 1148 
other disorders including ADHD, intellectual disability, language delay and genetic syndromes. 1149 





Table 2: Evidence-based medication in ASD (adapted from Lord et al285) [Au: please ensure this is added 1151 
to the third party rights table and we will obtain permission to reuse it on your behalf] 1152 
Medication FDA or EMA Indication 
and age  
Effect Size (d) Common Adverse 
Effects  
Typically used for ADHD symptoms 
Methylphenidate 
 
FDA and EMA approval 
for ADHD (not specific 
for ASD) in those ≥ 
6 years of age [Au: 









FDA and individual 
country approval for 
ADHD (not specific for 
ASD) in those ≥ 6 years 









FDA and EMA approval 
for ADHD (not specific 
for ASD) in those6–17 







pulse and blood 
pressure [Au:OK?]  
Typically used to treat agitation and irritability 
Risperidone FDA approval for 
irritability associated 
with ASD and EMA 
approval only for other 
indications [Au: what 
indications?] in 
those5–17 years of age 






Aripiprazole FDA approval for 
irritability associated 
with ASD and EMA 
d=0.87 
 






approval only for other 
indications [Au: what 
indications?] in those 
6–17 years of age 
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; EMA, European 1153 






Table 3: Factors that affect QOL. Cited within table: (Duncan & Bishop286) [Au: please ensure this is 1156 
added to the third party rights table and we will obtain permission to reuse it on your behalf] 1157 
Type of QOL Factor Description 
Objective QOL Early language  Follow-up studies of adults with ASD who were diagnosed as children 
have examined the amount of spoken language during early 
childhood. Individuals with ASD who had fluent speech are more likely 
to have higher levels of objective QOL life in adulthood than those 




Studies examining IQ scores using standardized IQ tests administered 
both in early childhood and adulthood find that individuals with ASD 
and  higher IQ scores have higher levels of objective QOL than those 
with lower IQ scores [Au: comparator ok?] . Other, less-standardized 
measures of intelligence (such as those used in large cohort studies 




Higher levels of adaptive behaviour – and particularly more activities 
of daily living – are associated with better objective QOL in people 
with ASD. Adaptive behaviour is a challenge for many individuals with 
ASD, who have scores below what would be expected based on IQ286. 
Adaptive behaviour is changeable, making it a promising avenue for 




Individuals with more severe autism symptoms tend to have lower 
objective QOL in adulthood. 
Challenging 
behaviours 
Higher levels of challenging behaviours in people with ASD, which can 
include both internalizing problems and externalizing problems, are 
related to lower objective QOL. 
Sex or gender Sex or gender associations with objective QOL have been 
demonstrated in terms of employment or post-secondary education. 
Indeed, women with ASD obtain employment and post-secondary 
educational positions at the same rate as men with ASD but have a 
more difficult time maintaining those positions over time. 
Subjective QOL Perceived stress Many adults with ASD perceive high levels of stress in their own lives. 
These perceptions are related to lower subjective QOL. 
Supports Several different types of supports have been related to subjective 
QOL, including formal services, support from family members (most 
often parents) and more general social support from others. 
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